ArticleGynecologic oncology reports2025
Association between time to adjuvant chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Delayed adjuvant chemotherapy (AC) worsens survival in advanced ovarian cancer (OC), but data on its impact after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is limited. We aimed to assess if delayed AC negatively affects survival in OC patients treated with CRS/HIPEC. Methods: We conducted a retrospective analysis of a single-center prospective database including FIGO stage III-IV epithelial OC patients who underwent initial CRS/HIPEC (upfront or interval) followed by AC. Patients were grouped into delayed AC (≥60 days) and no delay (<60 days). Patient characteristics were compared. Logistic regression identified risk factors for delay. Kaplan-Meier method and stratified Wilcoxon test were used for survival analysis. Results: Of 95 patients identified, 43 (45.3 %) were delayed, while 52 (54.7 %) had no delay. Delayed patients were significantly older (p = 0.013), had higher stage (p = 0.038) and peritoneal cancer index (PCI) (p = 0.020), more Clavien-Dindo grade III-IV complications (p = 0.002), and longer hospital stay (p = 0.003). Age ≥ 65 years (odds ratio [OR]: 5.25, p = 0.001), PCI ≥ 24 (OR: 3.89, p = 0.006), and stage IV (OR: 3.28, p = 0.017) were associated with a higher likelihood of delay. After adjusting for stage, comorbidities, complete cytoreduction (CC)-score, and CRS type, there were no significant differences in progression-free or overall (OS) survival between groups. Subgroup analysis found early chemotherapy worsened OS in CC-0 patients (p = 0.017), while CC-1 patients demonstrated a non-significant trend towards improved OS. Conclusion: Older OC patients with high tumor burden are more likely to have AC delay after CRS/HIPEC. Without clear survival benefits from early AC initiation, time to chemotherapy may be based on individual patient characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.